A Dose Escalation Study of R115777 (Zarnestra) Combined With Velcade (PS-341) in Patients With Relapsed Multiple Myeloma

Trial Profile

A Dose Escalation Study of R115777 (Zarnestra) Combined With Velcade (PS-341) in Patients With Relapsed Multiple Myeloma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Oct 2013

At a glance

  • Drugs Tipifarnib (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Oct 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 26 Mar 2009 Additional lead trial centres and lead investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top